MedTrace Logo

ICG Distribution Using NIF Imaging After IV Injection of ICG in Benign and Malignant Breast Cancer Tissue.

NCT01993576 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2014-10-15

No results posted yet for this study

Summary

The purpose of this study is to determine if NIF fluoresent imaging is an effctive approch to detect the margine of the breast tumoral tissue.

Conditions

  • Breast Cancer.

Interventions

DRUG

Indocyanine Green

Intravenous injection of 0.25 mg/kg Indocyanine Green (ICG) before the surgery

Sponsors & Collaborators

  • Jules Bordet Institute

    lead OTHER

Principal Investigators

  • Jean-Marie Nogaret, Prof. · Jules Bordet Institute

  • Isabelle Veys, MD · Jules Bordet Institute

  • Sophie VanKerckhove, biologist · Jules Bordet Institute

  • Philippe De Neubourg, MD · Jules Bordet Institute

  • Danielle Noterman, MD · Jules Bordet Institute

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01993576 on ClinicalTrials.gov